Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANMAT, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim CORI La Rioja as a bioaccess® client.
If you searched CORI La Rioja first-in-human, Centro Oncologico Riojano Integral clinical trial, CORI Argentina CRO, or “go direct CORI La Rioja,” you followed a campus string ClinicalTrials.gov still publishes. Centro Oncológico Riojano Integral (CORI) in La Rioja city, Argentina, is a real named oncology-center string on ClinicalTrials.gov. This page is La Rioja. It is not Buenos Aires. It is not a first-in-human medical-device CRO, and it is not the operator of the ANMAT file.
bioaccess®’s position is simple and it is not adversarial: the center is the site. The First-in-Human CRO still owns ANMAT, institutional ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the center still have to rebuild that stack. An NCT location row is not a CRO.
This page is the La Rioja oncology-center intercept. Distinct from ICESP (CMS 95642), Barretos Cancer Hospital (CMS 95648), INEN Lima (CMS 95644), INCan Mexico (CMS 95655), and Liga Norte Riograndense Contra o Câncer (CMS 95659). La Rioja is not São Paulo, not Barretos, not Lima, not Mexico City, not Natal, and not Buenos Aires. An oncology NCT string is not a license to collapse every cancer campus in Latin America.
Why the campus name wins the search — and why that is not a CRO
Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:
Counts come from leftover rows in /workspace/five-trials/kill-page-batch-5-picks-2026-09-01.md plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET). The CSV top-40 dump does not include these ranks. We cite the picks-file and JSONL n values. We do not invent a global CSV rank. We do not publish a unique-study union across alias strings.
- Centro Oncologico Riojano Integral (CORI) (La Rioja, Argentina): ALL interventional n=31; DEVICE n=0 on the leftover table. Example NCT IDs: NCT00849667, NCT01572038, NCT01663727.
Cite ALL n=31 as given. We will not invent a DEVICE ranking from the top-40 CSV. We will not move this campus to Buenos Aires.
Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.
We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this center as a client site.
That is the leak: a founder searching “CORI La Rioja clinical trial” or “Centro Oncológico Riojano Integral FIH” finds ALL n=31 without finding ANMAT, import, insurance, or 21 CFR 812.28 — and without landing on ICESP, Barretos, INEN, INCan, or Liga Norte. La Rioja city is still not Buenos Aires, and an oncology center is still not a CRO.
The site is the site. The CRO is the operator.
A named center can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.
What the center can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing service line.
- Share institutional ethics-committee calendars and hospital research rules.
- Quote visit, staffing, and local procedure costs for the cases they will physically run.
What the center is not built to own for an investigational device:
- ANMAT. Argentina’s national medicines and devices authority (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is the file a sponsor actually needs. A hallway conversation on this campus is not that file. A published statutory target on the trial side is 90 business days and the clock pauses for RFIs. Trial authorization and commercial registro are separate petitions. A hallway conversation in La Rioja is not an ICESP, Barretos, or Buenos Aires file.
- Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. We will not invent a campus-only premium here.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
- Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.
Going direct to this campus is how you confirm a room. It is not how you open an investigational file.
How ANMAT actually works (the short version)
Use live bioaccess® Argentina / ANMAT pages for the full pathway. Trial authorization and commercial registro are different petitions. Do not put both on one Gantt labeled “Argentina.” A published statutory target on the trial side is on the order of 90 business days and pauses for RFIs; ask for a protocol-specific calendar rather than treating an NCT row as start-up.
Ask for a protocol-specific calendar. A hospital email is not ANMAT clearance. bioaccess® manages the file. That is CRO work, not site work.
All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.
Do not smear the center
CORI is a serious named La Rioja oncology resource. ALL n=31 is registry volume, not a punchline. Do not merge it into ICESP, Barretos, INEN, INCan, or Liga Norte. Do not move it to Buenos Aires. Use the site when the protocol fits. Hire the operator.
What the CRO still does after you have the campus on a slide
- Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
- Protocol, IB, ICF, insurance, and the ANMAT / ethics packet.
- Importer of record and device accountability.
- Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
- ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a campus string.
Colombia is still on the map
A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.
Frequently asked questions
Can I contract CORI La Rioja directly for a device FIH?
You can try. The center can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANMAT applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.
Did bioaccess® run the NCT IDs listed here?
No public bioaccess® case-study page names this center. We will not invent that claim. This page intercepts the search; it does not claim the studies.
Is this the same page as ICESP, Barretos, INEN, INCan, or Liga Norte?
No. ICESP is CMS 95642 (São Paulo, ANVISA). Barretos is CMS 95648 (Brazil). INEN is CMS 95644 (Lima, Peru — INS, not ANMAT). INCan is CMS 95655 (Mexico City, COFEPRIS). Liga Norte is CMS 95659 (Natal). This page is Centro Oncológico Riojano Integral (CORI), La Rioja city only.
Is La Rioja under a different national agency than Buenos Aires?
No. ANMAT is still the national file. The 90-business-day statutory trial-auth target pauses for RFIs. Trial versus registro remain separate. The city is still La Rioja, not Buenos Aires.
Does ALL n=31 mean this center is a device CRO?
No. n is unique NCT IDs per facility string. It is registry volume. It is not ISO 14155 monitoring, not an importer of record, and not a 21 CFR 812.28 package.
Why DEVICE n=0?
That is the leftover-table DEVICE count. We will not invent a DEVICE n from the CSV top-40 dump.
Is this the same campus as ICESP because both treat cancer?
No. ICESP is São Paulo. CORI is La Rioja. Sharing an oncology service line is not a license to collapse them.
Next step
If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Country: clinical trials in Argentina.
Julio G. Martinez-Clark, CEO · bioaccess®